NRC — Preclinical in vivo facility

Q: How much funding can be received?

There is no informations about how much funding can be received.

Q: What is the deadline to apply?

The deadline to apply is not specified.

Q: Is the NRC — Preclinical in vivo facility a grant, loan, or tax credit?

NRC — Preclinical in vivo facility is a Researchers And Facilities

Q: Who are the financial supporters of the NRC — Preclinical in vivo facility?

NRC — Preclinical in vivo facility is funded by National Research Council Canada (NRC), Government of Canada

Q: Who is eligible for the NRC — Preclinical in vivo facility program?

To be eligible for the NRC — Preclinical in vivo facility program, you must: • Applicants must be biotechnology or biopharmaceutical companies. • Projects should involve the evaluation and functional characterization of biologics and vaccines.

Q: Who can I contact for more information about the NRC — Preclinical in vivo facility?

You can contact National Research Council Canada (NRC).

Q: Where is the NRC — Preclinical in vivo facility available?

The NRC — Preclinical in vivo facility program is available across Canada.

Q: Are startups eligible for the NRC — Preclinical in vivo facility program?

Yes, startups are eligible to apply for the NRC — Preclinical in vivo facility program.

Last Update: July 22, 2025

Canada

Preclinical in vivo facility for biologics and vaccines in Ottawa

At a glance

Eligible Funding

No Condition

Timeline

Open Date : November 14, 2019

Financing Type

Researchers And Facilities

Eligible Industries

Professional, scientific and technical services
Health care and social assistance

Funds Providers

Unspecified

Program status

Open

Overview

Fee-for-service facility that enables clients to validate their biologics and vaccine design approaches and obtain a clear picture of the preclinical safety and efficacy of their products.

Activities funded

This grant supports projects and activities centered on the evaluation and preclinical characterization of biologics and vaccines. These initiatives are designed to produce critical data for preparing Investigational New Drug (IND) applications.

Validation of therapeutic targets and biomarkers for cancer, infectious, inflammatory, and central nervous system (CNS) diseases.
Evaluation of biomarker/target expression, pharmacokinetics, pharmacodynamics, and brain penetration of biologics in cell, tissue, and animal models.
Vaccine uptake and distribution studies; evaluation of formulations for the induction of immune responses.
Efficacy studies in challenge models for infectious disease and cancer vaccines.
Animal model development for preclinical studies.
Development of novel molecular imaging tools, including nanocarriers and contrast agents.
Creation of methodologies for cell, tissue, and whole-body imaging in small animals.

Examples of admissible projects:

$ 100,000

Developing animal models to test the efficacy of a new brain cancer vaccine

$ 200,000

Developing novel molecular imaging tools for better visualization of brain tumors

$ 150,000

Evaluation of the efficacy of a new malaria vaccine using animal models

$ 180,000

Development of novel imaging tools for tracking nanocarrier drug delivery

$ 120,000

Evaluating the pharmacokinetics and pharmacodynamics of a new arthritis biologic

$ 200,000

Validation of new biomarkers for the early detection of Alzheimer's disease

Eligibility

I apologize, but it seems that the actual question is missing. Could you please provide the specific question regarding the eligibility criteria for the grant?

Who is eligible?

This grant is open to biotechnology and biopharmaceutical companies seeking to validate their biologics and vaccines through preclinical studies, leveraging NRC's specialized expertise and advanced facilities. Eligible applicants include organizations involved in therapeutic targets and biomarker validation for various diseases, biologics evaluation, and vaccine development.

Eligible expenses

The NRC's grant supports projects aimed at advancing the evaluation and development of biologics and vaccines, leveraging extensive expertise and state-of-the-art facilities. Eligible projects span various activities crucial for the preclinical safety and efficacy assessment of therapeutic interventions.

Validation of therapeutic targets and biomarkers for various diseases including cancer, infectious, inflammatory, and CNS diseases.
Evaluation of biomarker/target expression, pharmacokinetics, and pharmacodynamics.
Studies on vaccine uptake, distribution, and immune response validation.
Efficacy studies in challenge models for both infectious disease and cancer vaccines.
Development of animal models for preclinical studies.
Creation of novel molecular imaging tools and methodologies for small animal imaging.
Comprehensive imaging support using advanced optical and hyperspectral systems.

Eligible geographic areas

The funding information provided does not specify eligible geographical areas for companies applying for this grant. Therefore, the eligible locations cannot be determined from the given context.

Selection criteria

There are evaluation and selection criteria for this grant. The criteria include:

Validation of therapeutic targets and biomarkers for specific diseases
Evaluation of pharmacokinetics, pharmacodynamics, and brain penetration of biologics
Assessment of vaccine uptake, distribution, and immune response induction
Efficacy studies in challenge models for infectious disease and cancer vaccines
Development of novel molecular imaging tools and methodologies

How to apply

Contact Shawn Makinen or Maria Moreno to express interest and discuss project details

Provide necessary documentation and project information for review

Work with NRC's preclinical in vivo specialists to finalize project scope and objectives

Review and agree on project timelines, deliverables, and budget

Collaborate with the NRC's team throughout the project duration

Additional information

- The NRC's preclinical in vivo facility provides expertise in cancer, infectious, inflammatory, and CNS diseases. - Evaluation includes biomarker/target expression, pharmacokinetics, pharmacodynamics, and brain penetration of biologics in various models. - Vaccine studies cover uptake, distribution, immune response induction, and efficacy in challenge models. - Animal model development and customization are available. - The facility offers state-of-the-art imaging tools, from optical to microCT and mass spectrometry. - Experienced in working with various animal species and specialized surgical procedures. - Behavioral testing capabilities include maze tests. - Access to a range of imaging systems and microscopy platforms for detailed analysis. - The team at the facility has over 25 years of experience and can help with IND applications. - Good Animal Practice certification and ethical review processes are in place. - The location of the facility is in Ottawa, Ontario, Canada.

Documents and links

NRC — Preclinical in vivo facility

Apply to this program

Frequently Asked Questions about the NRC — Preclinical in vivo facility Program

Here are answers to the most common questions about the NRC — Preclinical in vivo facility. This section explains what the program is, how much funding is available, eligibility requirements, application deadlines, and other important details to help you determine if this grant is right for your business.